Navigation Links
Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh
Date:2/5/2010

SINGAPORE, UPPSALA, Sweden and CANTON, Mass., Feb. 5 /PRNewswire/ -- Novus Scientific Pte. Ltd today announced that the US Food and Drug Administration (FDA) has given the company 510(k) clearance to market the TIGR™ Matrix Surgical Mesh, for use in reinforcement of soft tissues where weakness exists. TIGR™ Matrix Surgical Mesh is a 100 percent resorbable, synthetic matrix, knitted from two different resorbable fibers that degrade at different rates following implantation. This unique patented dual-fibre design provides an initial high strength / high stability configuration, with gradually increasing compliance over time as the product is resorbed.  The macroporous structure is designed to allow tissue integration for reliable tissue repair.

TIGR™ Matrix Surgical Mesh is the world's first long-term resorbable, synthetic matrix, with dual stage mechanics, which is a significant new addition to the surgeon's toolbox.

"This technology is a new treatment option, which fills a gap in the market for ventral, incisional and inguinal hernia patients, and may avoid the potential long-term complications of permanent synthetic meshes," said Bruce Ramshaw, MD.

"It is very desirable to avoid leaving permanent foreign materials in the body. This provides us with a new tool to repair abdominal wall defects in a very logical way," said A/Prof. Stellan Bjorck of Sahlgrenska University Hospital, Gothenburg, Sweden.  A/Prof. Bjorck is the Principle Investigator for the first clinical study of the TIGR™ Matrix Surgical Mesh that recently completed enrollment.

"This new technology is exciting as it represents a breakthrough in hernia mesh repair -- TIGR™ Matrix Surgical Mesh is a new synthetic mesh that is 100% resorbable. From early clinical experience, it may provide a new therapeutic option for inguinal hernia and in the future for ventral and incisional hernia repair," said A/Prof. Davide Lomanto, President of the Asia-Pacific Hernia Society and Senior Consultant at National University Hospital, Singapore.

"We are very excited to be able to introduce the TIGR™ Matrix Surgical Mesh to US surgeons, as the first in a line of state-of-the-art synthetic resorbable medical devices," said Thomas Engstrom, CEO & President of Novus.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices.  Global HQ is in Singapore while European HQ and the core R&D function are in Uppsala, Sweden.   The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). Novus also has offices in the US and UK.

TIGR™ is a trademark of Novus Scientific Pte. Ltd.

CONTACT:  Ben Craven, +46-730-345522, ben.craven@novusscientific.com, or James Archetto, +1-781-577-2599, jim.archetto@novusscientific.com, both of Novus Scientific Pte. Ltd

SOURCE Novus Scientific Pte. Ltd

RELATED LINKS
http://www.novusscientific.com

'/>"/>

SOURCE Novus Scientific Pte. Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada
2. Derycz Scientific Featured In DDN (Drug Discovery News)
3. Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
4. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
5. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
6. International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia
7. Boston Scientific Announces Election of Nelda Connors to Its Board of Directors
8. Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health
9. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
10. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
11. Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):